Global Contact Us twitter LinkedIn gbt About Our Commitment Research Our MedicineInvestors & Media Careers OUR COMMITMENT Patients & Advocacy GBT’s Supported Conferences COVID-19 Information and Resources Corporate Giving The GBT Foundation Expanded Access OUR COMMITMENT GBT is advancing the care of people with sickle cell disease by developing breakthrough therapies, raising awareness and working to increase access to care GBT seeks to improve the lives of those with sickle cell disease (SCD) by combining focused science with compassion and collaboration. Our deep commitment to partnering with and advocating for the sickle cell community has been our guiding light since the beginning. First and foremost, we prioritize listening to and understanding the perspectives, interests and challenges patients face so we can develop important new investigational treatments and support access to care. We work with patient communities and healthcare providers to transform the quality of the care provided to people with SCD. Why we’ve made it a priority to partner with patients and advocates Patients are our focus. They are the true experts when it comes to knowing the impact of the disease and the challenges they face in receiving care Patients & Advocacy Supporting those who share our commitment to the sickle cell community We provide support and funding for researchers and advocacy groups Corporate Giving Learn about the sickle cell disease conferences we support Learn how stakeholders from across the SCD community share the latest advancements, future trends and ideas for improving patient care View meeting information Follow us on social media: Twitter LinkedIn gbt Copyright 2021 Global Blood Therapeutics, Inc. Privacy Policy Online Tracking Opt-Out Guide Terms Of Use Community Guidelines P-VOX-US-00501 ABOUT Our Company Leadership Board of Directors Contact Us CAREERS OUR COMMITMENT Patients & Advocacy GBT’s Supported Conferences COVID-19 Information and Resources Corporate Giving The GBT Foundation Expanded Access RESEARCH Sickle Cell Disease Pipeline Externally Sponsored Research (ESR) Partnerships Publications OUR MEDICINE INVESTORS & MEDIA Company Summary Media Resources Press Releases Events & Presentations Quarterly Results Analyst Coverage Stock Information SEC Filings Governance Investor FAQs This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page. Accept × The health and safety of patients, healthcare professionals and our employees is our highest priority. Learn more about our response to the COVID-19 pandemic, including the direct support we are providing to the sickle cell disease community. COVID-19 Information and Resources Close